Efficacy and Safety of Pediatric Drugs in Nasal Congestion

Inclusion Criteria: * Participants aged 10-17 years old with clinical symptoms of inflammatory of allergic nasal congestion in at least one nostril due to rhinitis or rhinopharyngitis (cold or flu); * Signed Consent; * Participants whose mother, father and / or legal guardian is in accordance with all study purposes and procedures; * Participants with clinical symptoms of nasal congestion in at least one nostril diagnosed through the Glatzel mirror; * Participants with minimal score of 2 points in the 0 to 3 scale (Moderate obstruction). Exclusion Criteria: * Participation in clinical trial in the year prior to this study; * Total obstruction of one of the nostrils by other etiologies that are not inflammatory or allergic; * Infectious bacterial-disease (clinically diagnosed); * Participants treated with antibiotic or possible antibiotic use due to another medical condition; * Use of intranasal corticosteroids (7 days prior to the study) or systemic (15 days prior to the study), regarding the plasma half-life of the drug; * Use of decongestants or antihistamine (intranasal or systemic) in the 03 days prior to the study; * Use of inhaled drugs (except nasal moisturizers such as saline solution) or treatment with immunosuppressants in the week before the study; * Participants with septum deviation grade II and III, nasal polyps, severe turbinate hypertrophy, adenoid hypertrophy, or other determining factors for nasal obstruction; * History of hyperthyroidism or hypertension; * History of hypersensitivity to the components of the study drugs; * History of transphenoidal hypophysectomy or oronasal surgery with exposure of the dura-mater; * Exclusive mouth-breathers patients; * Participants in chronic drug treatment for allergies (eg vaccines for allergy, cromolyn); * History of alcohol and / or drug abuse 3 months prior to the study; * Smokers * Pregnancy or risk of pregnancy and lactating patients; * PAny clinical, laboratory that, in the judgment of the investigator, may interfere with the safety of research participants.